New immune cell therapy tested for Tough-to-Treat liver cancer
NCT ID NCT06757881
Summary
This is an early-stage study to test the safety of a new type of immune cell therapy (CAR-T) for people with advanced liver cancer that has come back or hasn't responded to standard treatments. Researchers will give a small number of participants modified immune cells designed to target a specific protein on liver cancer cells. The main goal is to find a safe dose and understand the side effects before testing if the treatment is effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.